LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients

Contributed by: Business Wire

Logo

Tags

Mental Health

Research

Clinical Trials

Biotechnology

Other Health

Health

Pharmaceutical

General Health

Science

LivaNova PLC

More Like This

RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea

LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy

LivaNova Reports Second-Quarter 2024 Results

PR Newswire associated0

Neurolief Announces Breakthrough Results from Pivotal Clinical Trial of Brain Neuromodulation System for Treating Major Depressive Disorder

LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

LivaNova to Wind Down Advanced Circulatory Support Business Unit